OncoMatch/Clinical Trials/NCT06096779
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Is NCT06096779 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Bevacizumab for hepatocellular carcinoma.
Treatment: Atezolizumab · Bevacizumab — The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
Cannot have received: immune checkpoint blockade therapy
Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
Cannot have received: systemic immunostimulatory agent
Treatment with systemic immunostimulatory agents
Cannot have received: systemic immunosuppressive medication
Treatment with systemic immunosuppressive medication
Cannot have received: investigational therapy
Treatment with investigational therapy within 28 days prior to initiation of study treatment
Cannot have received: locoregional therapy to liver
Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
Lab requirements
Blood counts
Absolute neutrophil count ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support; Platelet count ≥ 50 × 10^9/L (50,000/μL) without transfusion; Hemoglobin ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
Kidney function
Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
Liver function
Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment; AST and ALT ≤ 5 × ULN; Serum bilirubin ≤ 3 × ULN; Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months; INR ≤2.3
Adequate hematologic and end-organ function Absolute neutrophil count ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support Platelet count ≥ 50 × 10^9/L (50,000/μL) without transfusion Hemoglobin ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL]) AST and ALT ≤ 5 × ULN Serum bilirubin ≤ 3 × ULN Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula) Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months International normalized ratio (INR) ≤2.3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona Cancer Center · Tucson, Arizona
- UC San Diego Moores Cancer Center · La Jolla, California
- University of Southern California-Keck School of Medicine -1975 Zonal Ave · Los Angeles, California
- University of Southern California · Newport Beach, California
- University of California Irvine Medical Center · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify